애플, 수요 불안정으로 아이폰 증산계획 취소(Bloomberg)
https://www.bloomberg.com/news/articles/2022-09-28/apple-ditches-iphone-production-increase-after-demand-falters
아래 기사 내용 전문입니다
————————————
Apple Ditches IPhone Production Increase After Demand Falters
2022-09-28 01:19:18.244 GMT
By Debby Wu and Takashi Mochizuki
(Bloomberg) -- Apple Inc. is backing off plans to increase
production of its new iPhones this year after an anticipated
surge in demand failed to materialize, according to people
familiar with the matter.
The Cupertino, California-based electronics maker has told
suppliers to pull back from efforts to increase assembly of the
iPhone 14 product family by as many as 6 million units in the
second half of this year, said the people, asking not to be
named as the plans are not public. Instead, the company will aim
to produce 90 million handsets for the period, roughly the same
level as the prior year and in line with Apple’s original
forecast this summer, the people said.
Demand for higher-priced iPhone 14 Pro models is stronger
than for the entry-level versions, according to some of the
people. In at least one case, an Apple supplier is shifting
production capacity from lower-priced iPhones to premium models,
they added.
Apple Sees Sustained iPhone Sales in 2022 as Market Slows
Apple had upgraded its sales projections in the weeks
leading up to the iPhone 14 release and some of its suppliers
had started making preparations for a 7% boost in orders. The
success of the company’s marquee device has implications for
wide swathes of the tech industry, with suppliers including
Taiwan Semiconductor Manufacturing Co. and Hon Hai Precision
Industry Co. depending on sales of iPhones and related devices
as key revenue drivers.
An Apple spokesperson declined to comment.
China, the world’s biggest smartphone market, is in an
economic slump that’s hit its domestic mobile device makers and
also affected the iPhone’s sales. Purchases of the iPhone 14
series over its first three days of availability in China were
11% down on its predecessor the previous year, according to a
Jefferies note on Monday.
Global demand for personal electronics has also been
suppressed by surging inflation, recession fears and disruption
from the war in Ukraine. The smartphone market is expected to
shrink by 6.5% this year to 1.27 billion units, according to
data from market tracker IDC.
“The supply constraints pulling down on the market since
last year have eased and the industry has shifted to a demand-
constrained market,” said Nabila Popal, research director at
IDC. “High inventory in channels and low demand with no signs of
immediate recovery has OEMs panicking and cutting their orders
drastically for 2022.”
https://www.bloomberg.com/news/articles/2022-09-28/apple-ditches-iphone-production-increase-after-demand-falters
아래 기사 내용 전문입니다
————————————
Apple Ditches IPhone Production Increase After Demand Falters
2022-09-28 01:19:18.244 GMT
By Debby Wu and Takashi Mochizuki
(Bloomberg) -- Apple Inc. is backing off plans to increase
production of its new iPhones this year after an anticipated
surge in demand failed to materialize, according to people
familiar with the matter.
The Cupertino, California-based electronics maker has told
suppliers to pull back from efforts to increase assembly of the
iPhone 14 product family by as many as 6 million units in the
second half of this year, said the people, asking not to be
named as the plans are not public. Instead, the company will aim
to produce 90 million handsets for the period, roughly the same
level as the prior year and in line with Apple’s original
forecast this summer, the people said.
Demand for higher-priced iPhone 14 Pro models is stronger
than for the entry-level versions, according to some of the
people. In at least one case, an Apple supplier is shifting
production capacity from lower-priced iPhones to premium models,
they added.
Apple Sees Sustained iPhone Sales in 2022 as Market Slows
Apple had upgraded its sales projections in the weeks
leading up to the iPhone 14 release and some of its suppliers
had started making preparations for a 7% boost in orders. The
success of the company’s marquee device has implications for
wide swathes of the tech industry, with suppliers including
Taiwan Semiconductor Manufacturing Co. and Hon Hai Precision
Industry Co. depending on sales of iPhones and related devices
as key revenue drivers.
An Apple spokesperson declined to comment.
China, the world’s biggest smartphone market, is in an
economic slump that’s hit its domestic mobile device makers and
also affected the iPhone’s sales. Purchases of the iPhone 14
series over its first three days of availability in China were
11% down on its predecessor the previous year, according to a
Jefferies note on Monday.
Global demand for personal electronics has also been
suppressed by surging inflation, recession fears and disruption
from the war in Ukraine. The smartphone market is expected to
shrink by 6.5% this year to 1.27 billion units, according to
data from market tracker IDC.
“The supply constraints pulling down on the market since
last year have eased and the industry has shifted to a demand-
constrained market,” said Nabila Popal, research director at
IDC. “High inventory in channels and low demand with no signs of
immediate recovery has OEMs panicking and cutting their orders
drastically for 2022.”
Bloomberg.com
Apple Ditches iPhone Production Increase After Demand Falters
Apple Inc. is backing off plans to increase production of its new iPhones this year after an anticipated surge in demand failed to materialize, according to people familiar with the matter.
9월 29일 장전 바이오 관련 뉴스
[한양증권 오병용]
퓨쳐켐, "전립선암 진단제 'FC303' 일본 특허 취득"
세레신, 시리즈 IIB 투자 라운드 유치 성공
셀트리온, 아바스틴 시밀러 ‘베그젤마' 美 FDA 판매허가 획득
삼성바이오에피스, 美 안과학회서 '아일리아 시밀러' 임상 중간 결과
시오노기, '경구용 코로나19' 3상서 "1차종결점 충족"
‘차세대 유전자편집’ 프라임, "2억弗 규모" IPO 추진
신라젠, 항암바이러스 'SJ-600' 시리즈 “특허출원”
대웅제약, 에이조스와 '합성치사 신약' 공동개발 계약
삼성에피스, '아일리아 시밀러' 3상 중간 "동등성 확인”
일동제약, '경구용 코로나19' 국내 2/3상 변경신청
한국피엠지제약 '듀록정100밀리그램'·'레일라정' 제조업무정지 처분
* 위 내용은 국내외 언론사 뉴스 등을 인용한 자료로 별도의 승인절차 없이 제공합니다.
[한양증권 오병용]
퓨쳐켐, "전립선암 진단제 'FC303' 일본 특허 취득"
세레신, 시리즈 IIB 투자 라운드 유치 성공
셀트리온, 아바스틴 시밀러 ‘베그젤마' 美 FDA 판매허가 획득
삼성바이오에피스, 美 안과학회서 '아일리아 시밀러' 임상 중간 결과
시오노기, '경구용 코로나19' 3상서 "1차종결점 충족"
‘차세대 유전자편집’ 프라임, "2억弗 규모" IPO 추진
신라젠, 항암바이러스 'SJ-600' 시리즈 “특허출원”
대웅제약, 에이조스와 '합성치사 신약' 공동개발 계약
삼성에피스, '아일리아 시밀러' 3상 중간 "동등성 확인”
일동제약, '경구용 코로나19' 국내 2/3상 변경신청
한국피엠지제약 '듀록정100밀리그램'·'레일라정' 제조업무정지 처분
* 위 내용은 국내외 언론사 뉴스 등을 인용한 자료로 별도의 승인절차 없이 제공합니다.
Yakup
[약업신문]퓨쳐켐, 전립선암 진단제 FC303 일본 특허 취득
방사성의약품 전문기업 퓨쳐켐은 전립선암 진단 후보물질 ‘FC303’의 일본 특허권을 취득했다고 28일 밝혔다. 특허명은 ‘전립선암 진단을 위한 PSMA-표적 방사성의약품’이다. 이번...